Top of the morning to you. How is everyone today? All set for another round of meetings and deadlines? Yes, of course, we understand. To prepare, please join us for a cup or two of stimulation or a water bottle if you prefer. And as always, here are a few items to help you along. We hope your day is pleasant and productive, and we look forward to being in touch. Good luck, everyone...
FDA Approves Roche's Herceptin For Stomach Cancer (Reuters)
FDA May Tighten Standards On Generics (Bloomberg News)
Actelion Vows To Stay Independent (Reuters)
Novartis Claims Its Alcon Offer Is More Attractive Now (Bloomberg News)
Lilly Experimental Diabetes Drug Fails (PharmaTimes)
Activists Fear Trade Deal To Hurt AIDS Care (Bangkok Post)
Covance Deal Signals Shift In CRO Relationships (R&D Directions)
Lilly Profit Rises on Cost Cutting (TheStreet)
WHO Begins Prequalification For Some APIs (InPharma-Technologist)
Novartis Profit Rises (Associated Press)
FDA Issues Warnings On Some Prostate Cancer Drugs (HealthDay)
Abbott Profit Falls On Solvay And Meridia Costs (Associated Press)
Genzyme Profit Rebounds As Shortages Ease (Boson Business Journal)
2 Comments
Turns out your colleagues at ProPublica,the editor Paul Steiger and the managing editor Steve Engelberg both head up a non profit receiving federal grants, make 570,000.00 and 450,000.00 respectfully. There seems to be some hypocrisy here.
DACP,
Can you point out in their 990 form where ProPublica receives federal grants? For your convenience, their 2009 form is here: http://propublica.s3.amazonaws.com/assets/docs/990-for2009.pdf
Seems like they are supported mostly by foundation money and some private donations. I don't see any federal or other government grants.
Also, do you know how those salaries compare to other award winning journalists of national prominence who live in New York City?
Please help us understand where exactly is the hypocrisy?